Samsung Bioepis’s biosimilar EPYSQLI® (eculizumab-aagh) was approved by the FDA on July 22, 2024. Alexion had sought a preliminary injunction to prevent the launch of EPYSQLI®, but the Delaware court ...

Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...

LEXINGTON, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VYGR), a biotechnology company dedicated to advancing ...

Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.

Susac syndrome is a rare inflammatory vascular endotheliopathy affecting the small vessels of the brain, eye, and ear.1,2 ...

Roche is taking on Alexion’s blockbuster Soliris (eculizumab), which was approved in NMOSD last year and in June Viela Bio, a spinoff from AstraZeneca, also won approval for another rival ...

Launched by AKF in November 2020, the UCKD Project works to expand access to genetic testing, reduce systemic inequities, engage providers and empower patients. Implementation groups have concentrated ...

helping lead the broader transition to a sustainable commercial enterprise through the company’s acquisition by Alexion Pharmaceuticals, Inc. in July 2015. Prior to joining Synageva, Mr. Bazemore ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases ...